Development Information. 16 5.2.1. Reports and Information Exchange ................. 16 5.2.2. Adverse Reaction Reporting ....................... 17 5.2.3. Clinical and Regulatory Audits ................... 17 5.3. Regulatory Approval Filings .............................. 17 5.4. Facilities Visits ........................................ 18
Appears in 2 contracts
Samples: Collaboration Agreement (Diacrin Inc /De/), Collaboration Agreement (Diacrin Inc /De/)
Development Information. 16 5.2.1. Reports and Information Exchange ................. Exchange....................... 16 5.2.2. Adverse Reaction Reporting ....................... 17 Reporting............................. 16 5.2.3. Clinical and Regulatory Audits ................... 17 Audits......................... 16 5.3. Regulatory Approval Filings .............................. 17 Filings..................................... 16 5.4. Facilities Visits ........................................ 18Visits............................................... 17
Appears in 1 contract
Samples: Collaboration Agreement (Geltex Pharmaceuticals Inc)
Development Information. 16 5.2.1. Reports and Information Exchange ................. Exchange......................................................16 5.2.2. Adverse Reaction Reporting ....................... 17 Reporting............................................................16 5.2.3. Clinical and Regulatory Audits ................... 17 Audits........................................................16 5.3. Regulatory Approval Filings .............................. 17 Filings....................................................................16 5.4. Facilities Visits ........................................ 18Visits..............................................................................17
Appears in 1 contract
Samples: Collaboration Agreement (Geltex Pharmaceuticals Inc)